Headquartered in London, Tithonia was founded in 2021 by Charlie Bryant and Nicolas Vennin, two entrepreneurs who spotted an opportunity to build a different kind of pharma company.

Their vision was to turn the traditional pharma model on its head. Instead of focusing on sales and top line growth, they started by building a company whose focus is on razor-sharp operations. Simple Pharma was born, a pharmaceutical platform company that holds licences and distributes medicines in 30+ countries across Europe and worldwide.

In 2022, Tithonia launched Androlabs, a specialty men's health pharma company whose mission is to close the male life expectancy gap. By providing the infrastructure for the products to reach the market with Simple Pharma, Tithonia enables Androlabs to fully focus on adding value to prescribers and patients. Androlabs was able to grow organically by more than 30% in its first two full years of trading.

In 2024, Tithonia partnered with Tamrisa, an entrepreneurial pharma company focused on tackling anti-microbial resistance. The story continues.

At Tithonia, we champion good, profitable growth, which is driven by combining our core values with a relentless focus on innovation and execution. Our core capabilities include strategic leadership, functional expertise, capital allocation, and identifying market opportunities for value creation.

The combined team stands at 40+ people, spread across 7 countries.